ataxia/stroke

RESEARCH SUPPORT The research for the present invention was supported in part by grants from the Multiple Sclerosis Society of Canada and the Canadian Myelin Research Initiative. FIELD OF THE INVENTION The present invention is concerned generally with glial cell components of the central nervous

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

FIELD OF INVENTION This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the I.kappa.B

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a Section 371 of International Application No. PCT/GB2004/005446, filed Dec. 23, 2004, which was published in the English language on Jul. 7, 2005, under International Publication No. WO 2005/060945 A2 and the disclosure of which is

FIELD OF THE INVENTION This invention relates in general to salicylanilide inhibitors of transcription factor NF-.kappa.B. Such compounds are particularly useful for treating diseases in which activation of NF-.kappa.B is implicated. More specifically, these compounds inhibit I.kappa.B

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION (1) Field of the Invention The present invention relates to therapeutic medical apparatus systems, delivery systems, devices and/or methods, and to apparatus and methods for using neural stimulation to alleviate the symptoms of movement disorders, such as those associated

BACKGROUND OF THE INVENTION Brain-derived neurotrophic factor (BDNF) is one of several endogenous proteins that play key roles in neuronal development. BDNF influences nerve growth as a neurotrophin and/or as a myokine. Therefore there is a need for improved methods for inducing expression of BDNF.

BACKGROUND OF THE INVENTION Brain-derived neurotrophic factor (BDNF) is one of several endogenous proteins that play key roles in neuronal development. BDNF influences nerve growth as a neurotrophin and/or as a myokine. Therefore there is a need for improved methods for inducing expression of BDNF.

BACKGROUND OF THE INVENTION Brain-derived neurotrophic factor (BDNF) is one of several endogenous proteins that play key roles in neuronal development. BDNF influences nerve growth as a neurotrophin and/or as a myokine. Therefore there is a need for improved methods for inducing expression of BDNF.

FIELD OF THE INVENTION The field of the invention pertains to activators of class I histone deacetylases and their uses in the treatment of neurological disorders. BACKGROUND OF THE INVENTION In a variety of neurodegenerative disorders such as ischemia and Alzheimer's disease (Hayashi et al.,